HHS pledges $23M to develop Merck’s experimental Ebola vaccine

In response to the Ebola outbreak in the Democtratic Republic of Congo, HHS will fund the development of Merck’s investigational Ebola vaccine.

Advertisement

The department will give Merck $23 million to produce V920 doses over the next year and will work with the drugmaker to help secure FDA approval for the vaccine. 

The agency’s response comes as the Ebola virus continues to spread in Congo. It has killed at least 1,900 people in the last year. 

As of Aug. 16, more than 192,000 people have been vaccinated with the experimental vaccine. 

More articles on pharmacy:
FDA approves AbbVie’s $59K rheumatoid arthritis drug
Teva launches generic version of EpiPen for kids
American Regent boosted price of essential hospital product by 1,300%

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The Performance Gap Your Pharmacy Training Metrics Can’t See

Monday, August 10
12:00 PM - 1:00 PM CDT

Presenters: Michael Alexander, AudirieDr. Tina Moen, PharmD, Colibri Healthcare

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.